Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 14, 2026Blood AdvancesOpen Access

Analysis of cell-free DNA in lymphomas: from sample collection to genotyping and minimal residual disease monitoring

View Full Paper
Ask AI
Bookmark
Share

Authors

DPDeborah PiffarettiCCChiara ConsoliDRDavide Rossi

Discussion

Loading...

Member takes

Overview

Review analyzes ctDNA assessment methods in lymphomas, highlighting clinical utility and future challenges.

Key Points

  • The aim is to evaluate the use of circulating tumor DNA (ctDNA) as a tool for monitoring lymphomas and assessing minimal residual disease.
  • Discussed various methods for ctDNA assessment, including droplet digital PCR and next-generation sequencing.
  • Explored pre-analytical and analytical workflows from blood collection to genotyping.
  • Outlined the importance of quality control and standardization in clinical applications.
  • ctDNA demonstrates high potential for non-invasive molecular profiling and monitoring treatment response.
  • Establishing ctDNA as a clinical-grade assay is a priority and requires standardization across procedures.
  • Large trials are in progress to validate ctDNA-based minimal residual disease assessment as a routine tool in lymphoma management.

Cite This Study

Piffaretti et al. (2026) studied this question.

synapsesocial.com/papers/6a2e4855b1cc60ccdea8ca4fhttps://doi.org/10.1182/bloodadvances.2024015609
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Circulating tumor DNA in B-cell lymphoma: technical advances, clinical applications, and perspectives for translational research2022 · 91 citations
  2. 2Circulating Tumor DNA as a Biomarker of Treatment Response and Minimal Residual Disease in Diffuse Large B-Cell Lymphoma: A Literature Review2026
  3. 3Real-world evaluation of ctdna for risk stratification across the spectrum of both aggressive and indolent lymphomas2025 · 1 citations
  4. 4ctDNA for MRD Assessment is Prognostic and Predictive in Newly Diagnosed and Relapsed/Refractory Lymphoma2026
  5. 5Dynamic Profiling of Cell Free Tumour DNA in Aggressive B‐Cell Lymphoma From Diagnosis to Transformation at Relapse2025